Pharmacology and Therapeutics of Bronchodilators

Pharmacological Reviews - Tập 64 Số 3 - Trang 450-504 - 2012
Mario Cazzola1, Clive Page, Luigino Calzetta, Maria Gabriella Matera
1Università di Roma Tor Vergata, Dipartimento di Medicina Interna, Via Montpellier 1, 00133 Roma, Italy. [email protected]

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.7326/0003-4819-146-8-200704170-00152

10.1067/mai.2002.129705

Ahrens, 1990, Skeletal muscle tremor and the influence of adrenergic drugs, J Asthma, 27, 11, 10.3109/02770909009073289

10.1067/mai.2001.119407

10.1378/chest.91.1.10

Aizawa, 1991, Effects of procaterol, a β2-adrenoceptor stimulant, on neuroeffector transmission in human bronchial tissue, Respiration, 58, 163, 10.1159/000195919

10.1378/chest.130.1.66

10.1136/thx.35.12.932

10.1136/thx.19.5.406

10.1016/S1081-1206(10)62505-7

10.1016/0024-3205(93)90729-M

10.1183/09031936.94.07030569

Anderson, 1986, Hemodynamic and non-bronchial effects of ipratropium bromide, Am J Med, 81, 45, 10.1016/0002-9343(86)90461-4

10.1164/ajrccm/147.5.1122

10.1111/j.1365-2222.1994.tb00991.x

10.1164/ajrccm.151.6.7767551

10.1042/cs0860291

Aparici, 2010, The in vitro pharmacological profile of LAS100977—a potent, selective and long-acting beta-2 receptor agonist (Abstract), Am J Respir Crit Care Med, 181, A5675

Aronson JK (2006) Theophylline, in Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 15th ed ( Aronson JK ed) pp 3361–3371, Elsevier Science, Amsterdam.

10.1378/chest.123.6.1964

10.1016/j.ahj.2004.03.048

10.1056/NEJM198107303050503

10.1161/01.CIR.100.3.274

Backer, 2007, Pharmaceutical treatment of asthma symptoms in elite athletes - doping or therapy?, Scand J Med Sci Sports, 17, 615, 10.1111/j.1600-0838.2007.00711.x

10.1136/thx.49.11.1103

Balint, 2010, Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone, Int J Chron Obstruct Pulmon Dis, 5, 311

10.1016/0024-3205(93)90310-Y

10.1164/ajrccm.152.3.7663795

10.1378/chest.117.2_suppl.63S

10.1164/rccm.200210-1142PP

10.1513/pats.200504-024SR

10.1016/0165-6147(92)90011-T

Barrett, 2010, In vitro pharmacological characterisation of GW642444, a novel long acting β2-agonist (LABA) using human recombinant β1/2/3 adrenoceptor cAMP assays (Abstract), Am J Respir Crit Care Med, 181, A4451

Barrett, 2010, Pharmacological characterisation of GW642444, a long-acting β2-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways (Abstract), Am J Respir Crit Care Med, 181, A4453

Barrington KJ Finer NN (2007) Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev (3):CD000509.

10.1016/S0954-6111(08)80071-6

10.1016/j.jaci.2009.07.043

10.1183/09031936.00138707

Bateman, 2008, Carmoterol—safety and tolerability of a long-acting β2 agonist in patients with COPD (Abstract), Proc Am Thorac Soc, 5, A653

10.1124/jpet.105.098251

10.1021/jm100068m

10.1378/chest.65.5.507

10.1016/S0140-6736(10)61158-0

Beeh, 2011, Once-daily NVA237 improves exercise endurance from first dose in patients with COPD: the GLOW3 trial (Abstract), Eur Respir J, 38, 819s

10.1523/JNEUROSCI.1168-07.2007

Beier, 2010, Efficacy and safety of single doses of inhaled LAS100977 in patients with persistent asthma (Abstract), Am J Respir Crit Care Med, 181, A5414

10.1016/j.pupt.2005.08.004

10.1513/pats.200504-043SR

10.1111/j.1476-5381.1996.tb15300.x

10.1073/pnas.84.24.8879

Berger, 2003, Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma, Ann Allergy Asthma Immunol, 90, 583, 10.1016/S1081-1206(10)61859-5

10.1165/rcmb.2007-0171OC

10.1016/0735-1097(91)90602-6

10.1111/j.1476-5381.1974.tb08593.x

10.1164/200809-1511OC

10.1016/S0140-6736(07)61906-0

10.1016/j.jaci.2006.06.036

10.1016/j.jaci.2006.02.045

10.1016/0091-6749(89)90101-2

10.1124/jpet.110.167007

Bouyssou, 2011, Synergistic bronchoprotective activity of the long-acting beta2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs (Abstract), Eur Respir J, 38, 613s

10.1016/j.bmcl.2009.12.087

Bouyssou, 2010, Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models (Abstract), Am J Respir Crit Care Med, 181, A4445

10.1016/S0029-7844(03)00621-5

10.1111/j.1476-5381.2009.00362.x

10.1056/NEJM199509283331301

Brown, 2011, Effect of olodaterol on the relaxation of small airways (Abstract), Eur Respir J, 38, 308s

Brunnée, 1992, Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma, Eur Respir J, 5, 982, 10.1183/09031936.93.05080982

10.1136/thx.2010.158568

10.1183/09031936.00191810

Bullowa, 1903, On the hypodermic use of adrenalin chloride in the treatment of asthmatic attacks, Med News, 83, 787

Burniston, 2007, Anabolic effects of a non-myotoxic dose of the β2-adrenergic receptor agonist clenbuterol on rat plantaris muscle, Muscle Nerve, 35, 217, 10.1002/mus.20684

Caccia, 1984, Kinetics and distribution of the beta-adrenergic agonist salbutamol in rat brain, J Pharm Pharmacol, 36, 200, 10.1111/j.2042-7158.1984.tb06941.x

10.1056/NEJMoa063070

10.1016/S0140-6736(09)61255-1

Canepa-Anson, 1987, Differences between acute and long-term metabolic and endocrine effects of oral β-adrenoceptor agonist therapy with pirbuterol for cardiac failure, Br J Clin Pharmacol, 23, 173, 10.1111/j.1365-2125.1987.tb03026.x

10.1152/japplphysiol.00313.2006

10.1016/S0034-5687(00)00208-5

10.1067/S0022-3476(03)00493-1

10.1053/rmed.2001.1105

10.1111/j.1398-9995.2008.01663.x

10.1378/chest.08-2041

Carstairs, 1985, Autoradiographic visualization of betaadrenoceptor subtypes in human lung, Am Rev Respir Dis, 132, 541

10.1124/jpet.109.152470

10.1124/jpet.111.179259

Castro, 2011, A new nitrosyl ruthenium complex nitric oxide donor presents higher efficacy than sodium nitroprusside on relaxation of airway smooth muscle, Eur J Pharm Sci, 43, 370, 10.1016/j.ejps.2011.05.004

Cates CJ Cates MJ (2008) Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev (3):CD006363.

Cates CJ Lasserson TJ Jaeschke R (2009) Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2):CD006924.

Cazzola, 2009, Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD, Curr Opin Investig Drugs, 10, 482

10.1016/j.pupt.2006.06.001

10.1007/s002280050561

10.1517/14740338.2010.500611

10.1111/j.1476-5381.2011.01216.x

10.1006/pupt.1999.0174

10.1006/pupt.2000.0267

10.1016/j.rmed.2004.05.003

10.1378/chest.126.1.220

10.1016/S0149-2918(02)85135-9

10.1378/chest.118.6.1576

10.1016/j.pupt.2003.09.001

10.1183/09031936.98.11061337

Cazzola, 1999, Long acting β2 agonists and theophylline in stable chronic obstructive pulmonary disease, Thorax, 54, 730, 10.1136/thx.54.8.730

Cazzola, 2002, Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction, Pulm Pharmacol Ther, 15, 97, 10.1006/pupt.2001.0336

Cazzola, 2006, The role of combination therapy with corticosteroids and long-acting β2-agonists in the prevention of exacerbations in COPD, Int J Chron Obstruct Pulmon Dis, 1, 345

Cazzola, 2010, Arformoterol tartrate in the treatment of COPD, Expert Rev Respir Med, 4, 155, 10.1586/ers.10.16

10.1378/chest.114.2.411

10.1016/j.ddstr.2006.09.009

10.1177/1753465807081747

10.1038/bjp.2008.284

10.1183/09031936.00013109

10.2165/00003495-200565120-00001

10.1517/13543784.14.7.775

10.1016/S0954-6111(98)90121-4

10.1016/0954-6111(95)90008-X

10.1016/j.pupt.2010.03.003

10.1378/chest.121.1.230

10.1016/j.rmed.2005.04.024

Cazzola, 2010, Roflumilast in chronic obstructive pulmonary disease: evidence from large trials, Expert Opin Pharmacother, 11, 441, 10.1517/14656560903555201

Cazzola, 2010, Indacaterol for chronic obstructive pulmonary disease (COPD), Drugs Today (Barc), 46, 139, 10.1358/dot.2010.46.3.1450070

10.1006/pulp.1994.1012

10.1053/rmed.2002.1456

10.1097/MCP.0b013e32833303d2

10.1080/15412550903156333

10.1378/chest.129.1.5

10.1378/chest.09-0011

10.1164/rccm.200712-1869OC

10.1378/chest.10-1830

Chapman, 2010, Pharmacology of SCH900182, a potent, selective inhibitor of PDE4 for inhaled administration (Abstract), Am J Respir Crit Care Med, 181, A5671

10.1111/j.1476-5381.2009.00352.x

Cheung, 1998, Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo, Am J Respir Crit Care Med, 158, 792, 10.1164/ajrccm.158.3.9801036

Choi, 2007, The effect of tiotropium and inhaled corticosteroid combination therapy in chronic obstructive pulmonary disease (COPD) and chronic obstructive bronchial asthma (COBA) associated with irreversible pulmonary function (Abstract), Am J Respir Crit Care Med, 175, A130

10.1164/ajrccm/140.1.137

10.1056/NEJMp1002074

10.1056/NEJMp1104375

10.1056/NEJMp1109621

10.1136/bmj.297.6662.1506

10.1007/s00228-009-0682-z

10.1016/S0091-6749(95)70031-5

10.1378/chest.90.1.45

Collomp, 2000, Effects of short-term oral salbutamol administration on exercise endurance and metabolism, J Appl Physiol, 89, 430, 10.1152/jappl.2000.89.2.430

10.1378/chest.105.5.1411

10.1378/chest.112.6.1514

10.1016/S0140-6736(01)05481-2

Conner, 1984, Mapping of β-adrenergic receptors in rat lung: effect of isoproterenol, Exp Lung Res, 6, 91, 10.3109/01902148409087898

10.1378/chest.108.2.401

10.1378/chest.89.3.394

Cope, 2011, Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease—a network meta-analysis, Int J Chron Obstruct Pulmon Dis, 6, 329, 10.2147/COPD.S18759

10.1136/thx.38.4.292

10.1084/jem.20040416

Coughlin, 1995, Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, Dilated Cardiomyopathy Study, Am J Epidemiol, 142, 395, 10.1093/oxfordjournals.aje.a117647

10.1016/S0163-7258(03)00004-4

10.1136/thx.2009.125435

Danto, 2007, A randomized, double-blind, placebo-controlled, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD (Abstract), Am J Respir Crit Care Med, 175, A131

Decramer, 2011, Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD (Abstract), Eur Respir J, 38, 150s

10.1164/ajrccm.157.3.9606120

de Mey, 2011, No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study, BMC Clin Pharmacol, 11, 7, 10.1186/1472-6904-11-7

10.1016/S0140-6736(00)02238-8

10.1038/nm.2237

10.2165/00002512-200724090-00003

De Troyer, 1978, Influence of beta-2 agonists on pressure-volume characteristics of the lungs, Am Rev Respir Dis, 118, 987

10.1016/j.pupt.2010.12.011

10.1016/j.coph.2010.03.002

Dixon, 1983, Changes in the bronchial reactivity of dogs caused by exposure to sulphur dioxide, J Physiol, 337, 89, 10.1113/jphysiol.1983.sp014613

10.1097/00005768-199606000-00005

10.1124/jpet.106.110635

10.1517/14728222.2011.580279

10.1513/pats.200505-047SR

10.1164/rccm.200910-1500OC

10.1056/NEJM199609193351202

10.1073/pnas.97.19.10483

10.1164/rccm.201005-0758OC

Ducharme FM Ni Chroinin M Greenstone I Lasserson TJ (2010a) Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev (4):CD005533.

Ducharme FM Ni Chroinin M Greenstone I Lasserson TJ (2010b) Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev (4):CD005535.

10.1136/thx.2004.036046

Du Plooy, 1994, The dose-related hyper- and hypokalaemic effects of salbutamol and its arrhythmogenic potential, Br J Pharmacol, 111, 73, 10.1111/j.1476-5381.1994.tb14025.x

10.1378/chest.119.5.1347

10.1186/1465-9921-12-156

Easton, 1986, A comparison of the bronchodilating effects of a β2-adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence, N Engl J Med, 315, 735, 10.1056/NEJM198609183151205

Edner, 1989, Effect of salbutamol on digoxin concentration in serum and skeletal muscle, Eur J Clin Pharmacol, 36, 235, 10.1007/BF00558153

Elkout, 2010, Use and safety of long-acting β2-agonists for pediatric asthma, Pediatric Health, 4, 295, 10.2217/phe.10.31

Ellis, 1997, Role of soluble guanylyl cyclase in the relaxations to a nitric oxide donor and to nonadrenergic nerve stimulation in guinea pig trachea and human bronchus, J Pharmacol Exp Ther, 280, 1215

Ellis, 1976, Pharmacokinetics of theophylline in children with asthma, Pediatrics, 58, 542, 10.1542/peds.58.4.542

Ellis, 1995, Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle, Br J Pharmacol, 116, 2510, 10.1111/j.1476-5381.1995.tb15103.x

Emala, 1997, Glucocorticoid treatment decreases muscarinic receptor expression in canine airway smooth muscle, Am J Physiol, 272, L745

El-Tawil S Al Musa T Valli H Lunn MP El-Tawil T Weber M (2010) Quinine for muscle cramps. Cochrane Database Syst Rev (12):CD005044

10.1056/NEJM199711133372002

10.1016/S0140-6736(09)61252-6

10.1016/j.rmed.2006.11.001

10.1186/1471-2466-10-11

10.1007/s11886-001-0035-8

10.1038/sj.bjp.0704039

10.1177/1753465807080740

10.1385/CRIAI:31:2:259

10.1016/j.jaci.2008.07.003

10.1016/j.drudis.2007.04.003

10.1016/j.rmed.2010.10.021

Ford, 2010, In vitro and in vivo pharmacological characterisation of GW642444, a novel long-acting β2 agonist (LABA), with fast onset and long duration in the guinea-pig (Abstract), Am J Respir Crit Care Med, 181, A5677

Ford, 2010, The therapeutic index of vilanterol trifenatate (Abstract), Eur Respir J, 24, 208s

10.1378/chest.09-2363

Formgren, 1970, A clinical comparison of inhaled terbutaline and orciprenaline in asthmatic patients, Scand J Respir Dis, 51, 203

Fox, 2007, Oral or inhaled corticosteroid combination therapy with low dose theophylline reverses corticosteroid insensitivity in a smoking mouse model (Abstract), Proc Am Thorac Soc, 2, A637

10.1038/clpt.1986.183

Freedman, 1972, Trial of a terbutaline aerosol in the treatment of asthma and a comparison of its effects with those of a salbutamol aerosol, Br J Dis Chest, 66, 222, 10.1016/0007-0971(72)90033-2

Freeman, 1992, The effect of ipratropium bromide on maximal exercise capacity in asthmatic and non-asthmatic men, Respir Med, 86, 151, 10.1016/S0954-6111(06)80232-5

10.1378/chest.89.2.249

Fugleholm, 1993, Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma, Eur Respir J, 6, 1474, 10.1183/09031936.93.06101474

10.1378/chest.11-0406

10.1159/000237698

Gandevia, 1975, Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders, Postgrad Med J, 51, 13

10.1124/jpet.109.151639

Gelb, 2011, ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients (Abstract), Eur Respir J, 38, 149s

Gershon, 2011, Comparison of inhaled long-acting β-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study, Ann Intern Med, 154, 583, 10.7326/0003-4819-154-9-201105030-00003

10.1111/j.1474-8673.1991.tb00260.x

Glossop, 2010, Inhalation by design: novel ultra-long-acting β2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup, J Med Chem, 53, 6640, 10.1021/jm1005989

10.1111/j.1365-2125.1986.tb02956.x

Gongora, 1991, A single dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects, Am Rev Respir Dis, 144, 626, 10.1164/ajrccm/144.3_Pt_1.626

10.1016/j.ejphar.2003.10.027

10.2174/138955706776073402

Gray, 1982, A comparative double-blind study of the bronchodilator effects and side effects of inhaled fenoterol and terbutaline administered in equipotent doses, Br J Dis Chest, 76, 341, 10.1016/0007-0971(82)90068-7

Green, 1996, Sustained activation of a G protein-coupled receptor via “anchored” agonist binding. Molecular localization of the salmeterol exosite within the β2-adrenergic receptor, Biol Chem, 271, 24029, 10.1074/jbc.271.39.24029

10.1006/pulp.1995.1001

10.1021/bi00198a006

Greenough, 1993, Inhaled ipratropium bromide and terbutaline in asthmatic children, Respir Med, 87, 111, 10.1016/0954-6111(93)90137-O

10.1016/S1094-5539(02)00172-4

10.1378/chest.126.6.1946

10.1016/j.ejphar.2005.12.072

Gryglewski, 1970, The inactivation of noradrenaline and isoprenaline in dogs, Br J Pharmacol, 39, 573, 10.1111/j.1476-5381.1970.tb10365.x

Gu Q Lee LY (2006) Neural control of airway smooth muscle, in Encyclopedia of Respiratory Medicine ( Laurent GJ Shapiro SD eds) pp 138–145, Elsevier, Amsterdam.

10.1016/0091-6749(84)90235-5

10.1016/j.anai.2010.12.008

Gutke, 2005, AWD-12-281 (inhaled) (elbion/GlaxoSmithKline), Curr Opin Investig Drugs, 6, 1149

Haalboom, 1985, Hypokalaemia induced by inhalation of fenoterol, Lancet, 1, 1125, 10.1016/S0140-6736(85)92432-8

Haeussermann, 2006, Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD (Abstract), Eur Respir J, 28, 211s

Hamad, 1997, Regulation of cGMP by soluble and particulate guanylyl cyclases in cultured human airway smooth muscle, Am J Physiol, 273, L807

10.1152/ajplung.00033.2003

10.1016/j.pupt.2007.12.004

Hanania NA Feldman G Zachgo W Shim JJ Crim C Sanford L Lettis S Barnhart F Haumann B (2012) The efficacy and safety of the novel long-acting β2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest http://dx.doi.org/10.1378/chest.11-2231 .

10.1164/ajrccm.165.8.200111-091bc

10.1016/j.rmed.2004.10.014

10.1186/1465-9921-8-19

Hardy, 1992, Bronchodilation effect of oxitropium bromide compared with ipratropium bromide (Abstract), Thorax, 48, 865

10.1093/qjmed/93.11.761

10.2217/14622416.9.3.349

10.1093/eurjhf/hfq040

Herrmann, 1937, Successful treatment of persistent extreme dyspnea, ‘status asthmaticus’—Use of theophylline ethylene diamine (aminophylline, U.S.P.) intravenously, J Lab Clin Med, 23, 135

10.1183/09031936.00147706

Hirsch, 1922, Klinischer und Experimenteller Beitrag zur KrampRosenden wirkung der purinderivate, Klinische Wochenschrift, 1, 61, 10.1007/BF01714150

Hodder, 2007, Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids, Int J Chron Obstruct Pulmon Dis, 2, 157

10.1164/ajrccm/148.6_Pt_1.1474

10.1016/0024-3205(90)90123-9

Hughes, 2011, Dual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary disease, Bioorg Med Chem Lett, 21, 1354, 10.1016/j.bmcl.2011.01.043

Hulland, 2011, Duration of ingle and dual pharmacology in vivo of PF-4348235: a novel inhaled dual antimuscarinic/ß2 agonist in conscious guinea pigs (Abstract), Am J Respir Crit Care Med, 183, A1610

Ida, 1976, Cardiorespiratory activities of 3-formylamino-4-hydroxy-α-(N-1-methyl-2-p-methoxyphenethylaminomethyl)-benzylalcohol-hemifumarate (BD 40A) and some other β-adrenoceptor stimulants in conscious guinea pigs, Arzneimittelforschung, 26, 1337

Ida, 1976, Comparison of the action of BD 40 A and some other β-adrenoceptor stimulants on the isolated trachea and atria of the guinea pig, Arzneimittelforschung, 26, 839

10.1136/thx.50.1.62

Inman, 1996, The effect of regular inhaled albuterol on exercise-induced bronchoconstriction, Am J Respir Crit Care Med, 153, 65, 10.1164/ajrccm.153.1.8542164

Inoue, 2009, Investigation of β2-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic β-adrenergic receptor stimulant, J Obstet Gynaecol Res, 35, 405, 10.1111/j.1447-0756.2008.01001.x

10.1164/ajrccm.162.1.9907092

10.1016/S0140-6736(04)17273-5

Ito, 2001, Possible involvement of Rho kinase in Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle, Am J Physiol Lung Cell Mol Physiol, 280, L1218, 10.1152/ajplung.2001.280.6.L1218

10.1073/pnas.132556899

10.1183/09031936.00014108

10.1111/j.1365-2125.1991.tb05571.x

Jackson, 2010, “Divine stramonium”: the rise and fall of smoking for asthma, Med Hist, 54, 171, 10.1017/S0025727300000235

10.1165/ajrcmb.24.4.4379

10.1164/rccm.200804-494OC

10.1046/j.1365-201X.1998.00462.x

Jansat, 2009, Safety and pharmacokinetics of single doses of aclidiniium bromide, a novel long-acting antimuscarinic in healthy subjects, Int J Clin Pharmacol Ther, 47, 460, 10.5414/CPP47460

Jenne, 1998, Can oral β2 agonists cause heart failure, Lancet, 352, 1081, 10.1016/S0140-6736(05)79750-6

10.1378/chest.10045

Johnson, 1998, The β-adrenoceptor, Am J Respir Crit Care Med, 158, S146, 10.1164/ajrccm.158.supplement_2.13tac110

10.1053/prrv.2000.0102

10.1016/0024-3205(93)90728-L

Jones, 2011, Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD, Bioorg Med Chem Lett, 21, 2759, 10.1016/j.bmcl.2010.10.132

Jones, 2011, Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN (Abstract), Am J Respir Crit Care Med, 183, A6350

10.1186/1465-9921-12-55

Jones, 1990, Selective inhibition of relaxation of guinea-pig trachea by charybdotoxin, a potent Ca++-activated K+ channel inhibitor, J Pharmacol Exp Ther, 255, 697

10.1139/y80-148

10.1016/j.rmed.2009.12.003

10.1164/ajrccm.153.1.8542105

Källström, 1994, The interaction between salmeterol and β2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro, Br J Pharmacol, 113, 687, 10.1111/j.1476-5381.1994.tb17047.x

10.1080/02770900802348321

Kanniess, 2008, Acute effect of carmoterol, a long-acting β2-agonist, in patients with COPD (Abstract), Proc Am Thorac Soc, 5, A655

Kapoor, 2009, The efficacy of tiotropium as a steroid-sparing agent in severe asthma, Can Respir J, 16, 99, 10.1155/2009/206506

10.1007/BF00562439

10.2165/00151829-200403040-00005

Kelleher, 2011, Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD) (Abstract), Eur Respir J, 38, 140s

Kelly, 2009, β2-Receptor polymorphisms in asthma, Lancet, 374, 1726, 10.1016/S0140-6736(09)61639-1

Kempsford, 2011, The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination (Abstract), Eur Respir J, 38, 138s

Kempsford, 2010, GW642444, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in asthmatic patients (Abstract), Am J Respir Crit Care Med, 181, A5413

Kempsford, 2010, GW642444, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients (Abstract), Am J Respir Crit Care Med, 181, A4447

10.1016/j.jaci.2011.04.039

Kerwin, 2011, ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide (Abstract), Eur Respir J, 38, 149s

10.1111/j.1469-7793.1999.0843p.x

Kikis, 1982, Influence of ipratropium bromide on heart rate and hemodynamics in patients with sinus bradycardia, Clin Cardiol, 5, 441, 10.1002/clc.4960050804

10.1124/mol.53.1.128

Kikkawa, 1994, TA-2005, a novel, long-acting and selective β2-adrenocepter agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other β2-agonists, Biol Pharm Bull, 17, 1047, 10.1248/bpb.17.1047

Kikkawa, 1991, Tracheal relaxing effects and β2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea-pig tissues, Jpn J Pharmacol, 57, 175, 10.1254/jjp.57.175

10.1016/j.rmed.2008.10.025

10.1378/chest.104.4.1101

Kizer, 1999, Blurred vision from ipratropium bromide inhalation, Am J Health Syst Pharm, 56, 914, 10.1093/ajhp/56.9.914a

Knudson, 1967, An effect of isoproterenol on ventilation-perfusion in asthmatic versus normal subjects, J Appl Physiol, 22, 402, 10.1152/jappl.1967.22.3.402

10.1111/j.1440-1843.2004.00573.x

10.1016/j.rmed.2011.02.008

10.1183/09031936.00045810

10.1016/S0002-9343(99)00222-3

Kossel, 1888, Uber eine neue Base aus dem Pflanzenreich, Berichte der Deutschen chemischen Gesellschaft, 21, 2164, 10.1002/cber.188802101422

Kottakis, 2006, Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma (Abstract), Eur Respir J, 28, 665s

10.1378/chest.101.6.1545

10.1146/annurev.pharmtox.38.1.289

10.1001/jama.2010.357

10.1073/pnas.89.22.11051

Kuna, 2011, Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD (Abstract), Eur Respir J, 38, 148s

10.1001/jama.1982.03320310034024

10.1016/S0167-0115(02)00099-X

LaForce, 2008, Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study, Allergy, 63, 103, 10.1111/j.1398-9995.2007.01555.x

10.1016/j.pupt.2010.06.005

10.1124/jpet.103.061739

Lainé, 2011, The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing (Abstract), Eur Respir J, 38, 613s

10.1136/thx.2003.019059

10.7326/0003-4819-149-6-200809160-00004

10.1378/chest.91.5.662

10.1378/chest.105.6.1701

Levenson M (2008) Long-acting beta-agonists and adverse asthma events meta-analysis. Statistical briefing package for joint meeting of the FDA Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee, December 2008. Available at http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf .

Li, 2009, Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist (Abstract), Eur Respir J, 34, 777s

Libersa, 1988, Comparative cardiac effects of intravenous bolus of ipratropium bromide (itrop) and atropine sulfate in 22 patients, Clin Cardiol, 11, 454, 10.1002/clc.4960110704

10.1016/S0954-6111(03)00031-3

10.1016/S0009-9236(99)70071-8

10.1136/thx.48.5.547

10.1042/cs0960253

10.1016/0002-9343(89)90438-5

10.1136/thx.50.1.54

10.1164/rccm.200709-1363OC

Littner, 2000, Long acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive disease, Am J Respir Crit Care Med, 161, 1136, 10.1164/ajrccm.161.4.9903044

10.1111/j.1398-9995.1989.tb01068.x

10.1016/j.ejps.2009.10.001

10.1136/thx.2008.110916

10.1006/pupt.2002.0400

Lötvall, 2010, Safety and efficacy of fluticasone furoate/vilanterol trifenatate in COPD patients (Abstract), Eur Respir J, 24, 1013s

Lötvall, 2010, Dose-related efficacy of vilanterol trifenatate, a long-acting beta2 agonist with inherent 24-hour activity, in patients with persistent asthma (Abstract), Eur Respir J, 24, 1013s

10.1067/mai.2001.119152

Macht, 1921, A study of antispasmodic drugs on the bronchus, J Pharmacol Exp Ther, 18, 373

Macintyre, 2009, A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a β2 adrenoreceptor agonist, PF-00610355 (Abstract), Eur Respir J, 34, 344s

Magnussen, 1987, Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics, Am Rev Respir Dis, 136, 1163, 10.1164/ajrccm/136.5.1163

10.1164/rccm.200903-0388OC

Mahler, 2011, Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone (Abstract), Am J Respir Crit Care Med, 183, A1591

10.1016/0014-2999(96)00104-5

Make, 2008, Efficacy of 3 different doses of carmoterol, a long-acting β2-agonist in patients with COPD (Abstract), Proc Am Thorac Soc, 5, A961

Malani, 1982, Ipratropium bromide induced angle closure glaucoma, N Z Med J, 95, 749

Maltais, 2010, Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients (Abstract), Eur Respir J, 24, 1014s

Maltin, 1993, Effect of protease inhibitors and clenbuterol on the in vitro degradation of dystrophin by endogenuous proteases in human skeletal muscle, Biosci Rep, 13, 159, 10.1007/BF01149960

10.1136/bmj.289.6443.469

10.1016/0895-4356(95)00555-2

Marshall, 2010, The effect of different dosages of caffeine on time to exhaustion in prolonged exercise in trained athletes (a meta analysis), The Plymouth Student Scientist, 3, 18

10.1080/02770900801971792

10.1172/JCI119874

10.1016/j.jaci.2010.02.003

Maspero, 2010, Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma, J Asthma, 47, 1106, 10.3109/02770903.2010.514634

10.1016/j.pupt.2009.04.005

10.1111/j.1476-5381.2011.01339.x

10.1016/S0954-6111(96)90178-X

10.2165/00003495-200767040-00002

10.1006/pulp.1995.1036

10.1016/j.pupt.2009.10.001

10.1016/j.tips.2011.04.003

10.1378/chest.10072

Mazza, 1982, Xanthines in respiratory diseases, Can Fam Physician, 28, 1799

10.1113/expphysiol.2010.054635

10.1164/ajrccm/146.4.912

McDaniel, 1992, Nitrovasodilators relax arterial smooth muscle by decreasing [Ca2+]i and uncoupling stress from myosin phosphorylation, Am J Physiol, 263, C461, 10.1152/ajpcell.1992.263.2.C461

10.1016/0091-6749(81)90164-0

10.1172/JCI200318193

10.1097/00042752-200207000-00004

10.1124/pr.56.2.4

McNamara, 2009, Comparative preclinical efficacy of combivent and a novel, bifunctional muscarinic antagonist and β2-adrenergic agonist (Abstract), Am J Respir Crit Care Med, 179, A4573

Mehta, 2011, Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults (Abstract), Eur Respir J, 38, 723s

Mehta, 2011, Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD (Abstract), Eur Respir J, 38, 138s

10.1164/ajrccm.149.5.8173753

Meurs, 2011, The bronchoprotective efect of olodaterol against histamine is synergistically enhanced and prolonged by tiotropium bromide (Abstract), Am J Respir Crit Care Med, 183, A1379

Miller, 1980, A comparison of oral terbutaline and fenoterol in asthma, Ann Allergy, 44, 15

10.1016/j.rmed.2007.02.010

Miraldi, 2001, Distribution of hyoscyamine and scopolamine in Datura stramonium, Fitoterapia, 72, 644, 10.1016/S0367-326X(01)00291-X

Miralpeix, 2010, LAS100977, a novel β2-agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs (Abstract), Eur Respir J, 24, 218s

10.1056/NEJM197309202891202

10.2165/11203960-000000000-00000

10.1164/ajrccm/148.5.1238

Molimard, 1998, Long- and short-acting β2 adrenoceptor agonists: interactions in human contracted bronchi, Eur Respir J, 11, 583, 10.1183/09031936.98.11030583

Moore, 2011, Influence of gene–gene interactions on response to albuterol therapy, Pharmacogenomics, 12, 1, 10.2217/pgs.10.192

10.1016/0091-6749(89)90477-6

10.1136/pgmj.68.796.132

10.1046/j.1365-2125.2003.01760.x

Naline, 2010, β2 agonist intrinsic activity: comparison of BI 1744 and formoterol in different functional settings (Abstract), Am J Respir Crit Care Med, 181, A4443

10.1183/09031936.00032806

Naline, 1994, Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus, Eur Respir J, 7, 914, 10.1183/09031936.94.07050914

Nandeuil, 2006, Safety and tolerability of the novel very long acting β2-agonist carmoterol given as a 2 μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma (Abstract), Eur Respir J, 28, 665s

Nannini LJ Cates CJ Lasserson TJ Poole P (2007a) Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (4):CD006826.

Nannini LJ Cates CJ Lasserson TJ Poole P (2007b) Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (4):CD006829.

Nannini LJ Cates CJ Lasserson TJ Poole P (2007c) Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (4):CD003794.

Nardi, 2008, Potassium channels as drug targets for therapeutic intervention in respiratory diseases, Expert Opin Ther Pat, 18, 1361, 10.1517/13543770802553798

10.1084/jem.20010897

10.1016/j.jaci.2007.09.029

10.1016/j.jaci.2004.10.023

10.1378/chest.129.1.15

10.1016/j.pupt.2004.04.002

10.1378/chest.105.6.1738

Newnham, 1991, The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic responses to inhaled terbutaline, Br J Clin Pharmacol, 32, 630, 10.1111/j.1365-2125.1991.tb03965.x

10.1097/00005344-200207000-00017

10.1073/pnas.0810902106

10.1016/0014-2999(94)90392-1

10.1111/j.1476-5381.1993.tb13929.x

Nicholson, 1994, Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes—their potential utility in the therapy of asthma, Pulm Pharmacol, 7, 1, 10.1006/pulp.1994.1001

Norman, 2009, Which of three structures is AZD-3199? WO-2008104790, WO-2008096112 and WO-2008096119, Expert Opin Ther Pat, 19, 1157, 10.1517/13543770902815527

Norris, 2011, The pharmacodynamics of GSK961081 in patients with COPD (Abstract), Eur Respir J, 38, 138s

10.1378/chest.10792

10.1016/j.jaci.2009.08.047

10.1016/j.rmed.2011.03.014

O'Donnell, 1994, Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis, J Pharmacol Exp Ther, 270, 1289

10.1016/0014-2999(72)90104-5

O'Donnell, 1978, Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on β-adrenoceptors in guinea-pig trachea, Eur J Clin Pharmacol, 47, 333, 10.1016/0014-2999(78)90241-8

10.1186/1465-9921-11-130

10.1378/chest.08-2367

Ohmori, 2004, Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15, 20, 21, L17]-VIP-GRR (IK312532), Regul Pept, 123, 201, 10.1016/j.regpep.2004.04.029

Oksuz, 2007, Acute angle-closure glaucoma precipitated by local tiotropium absorption, Pulm Pharmacol Ther, 20, 627, 10.1016/j.pupt.2006.07.002

Oleson, 2010, ALKS 27 (Trospium inhalation powder) improves lung function following single administration in subjects with COPD (Abstract), Am J Respir Crit Care Med, 181, A4457

10.1161/CIRCULATIONAHA.107.760405

10.1023/A:1016322524471

Onoue, 2007, Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD, Peptides, 28, 1640, 10.1016/j.peptides.2007.04.009

10.1136/bmj.c3134

10.1177/0960327110363335

Page, 1993, An explanation of the asthma paradox, Am Rev Respir Dis, 147, S29, 10.1164/ajrccm/147.6_Pt_2.S29

10.1016/j.pupt.2010.04.002

10.1183/09031936.98.12010024

10.1016/S0091-6749(99)70271-X

Pahl, 2006, Synergistic effects of the anti-cholinergic R,R-glycopyrrolate with anti-inflammatory drugs, Biochem Pharmacol, 72, 1690, 10.1016/j.bcp.2006.07.025

10.1136/thx.2006.059386

10.1093/hmg/ddg125

Palmqvist, 1999, Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients, Am J Respir Crit Care Med, 160, 244, 10.1164/ajrccm.160.1.9901063

10.1371/journal.pone.0011819

10.1111/j.1398-9995.2008.01876.x

10.1111/j.1532-5415.2004.52110.x

Patel, 2011, The in-vitro pharmacology of PF-4348235 at native receptors—a novel inhaled dual antimuscarinic/beta2 adrenoceptor agonist (Abstract), Am J Respir Crit Care Med, 183, A1608

Patel, 2010, The in vitro pharmacology of PF-3429281—A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist (Abstract), Eur Respir J, 24, 218s

Patel, 2010, The in vitro pharmacology of PF-4522971—A novel inhaled muscarinic M3 antagonist (Abstract), Eur Respir J, 36, 219s

Paul, 2010, Revisiting an old therapy: theophylline in asthma, J Asthma Allergy Educ, 1, 180, 10.1177/2150129710372963

10.1378/chest.10047

Penna, 1993, Systemic absorption of salbutamol following nebulizer delivery in acute asthma, Acta Pediatr, 82, 963, 10.1111/j.1651-2227.1993.tb12609.x

10.1378/chest.72.6.731

10.1016/j.pupt.2008.09.006

Persson, 1991, Pharmacology of anti-asthma xanthenes, Handb Exp Pharmacol, 98, 207, 10.1007/978-3-642-75855-3_7

Philip, 2010, Demonstration of dual pharmacology in vivo of PF-3429281: a novel inhaled dual antimuscarinic/β2 agonist (Abstract), Eur Respir J, 24, 218s

10.1067/mai.2002.129702

Physician's Desk Reference (1998) Medical Economics Company, Montvale, NJ.

10.1136/thx.34.1.45

Plotnick LH Ducharme FM (2000) Combined inhaled anticholinergic agents and beta-2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev (2):CD000060.

10.1046/j.0905-6157.2003.00096.x

Poli, 2009, harmacokinetic and pharmacodynamic interaction of carmoterol and budesonide in asthmatic patients (Abstract), Am J Respir Crit Care Med, 179, A2789

10.1164/rccm.200612-1864OC

Pras, 1991, Urinary retention associated with ipratropium bromide, DICP, 25, 939, 10.1177/106002809102500907

10.1111/j.1365-2222.1982.tb01640.x

10.2165/00003495-198938010-00004

10.1021/jm100326d

Profita, 2011, β2 long-acting and anticholinergic drugs synergistically control TGFβ1-mediated neutrophilic inflammation in COPD: an “in vitro” model (Abstract), Eur Respir J, 38, 694s

10.1513/pats.200504-038SR

10.1016/j.bmcl.2006.01.006

10.1016/j.bmcl.2007.03.047

Pulido-Rios, 2009, TD-5959: a novel bifunctional muscarinic antagonist–β2-adrenergic agonist with potent and sustained in vivo bronchodilator activity in guinea pigs (Abstract), Am J Respir Crit Care Med, 179, A6195

Pullerits, 2011, The duration of bronchodilation of salmeterol and salbutamol as measured by specific airway conductance in healthy subjects, Pulm Pharmacol Ther, 24, 55, 10.1016/j.pupt.2010.10.006

10.1016/j.annemergmed.2005.02.001

10.1164/ajrccm/147.6_Pt_1.1436

10.1016/j.ejphar.2005.12.050

10.1016/j.pupt.2004.03.001

10.1016/0954-6111(94)90042-6

Ramsdale, 1991, Prolonged protection against methacholine-induced bronchoconstriction by the inhaled β2-agonist formoterol, Am Rev Respir Dis, 143, 998, 10.1164/ajrccm/143.5_Pt_1.998

10.1038/nature09648

10.1038/nature10361

10.1016/j.ejphar.2005.12.069

10.1165/ajrcmb/8.3.334

10.1016/j.tem.2006.03.008

Renard, 2011, Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches, Respir Res, 12, 54, 10.1186/1465-9921-12-54

Restrepo, 2007, Use of inhaled anticholinergic agents in obstructive airway disease, Respir Care, 52, 833

Richardson, 1976, Nonadrenergic inhibitory nervous system in human airways, J Appl Physiol, 41, 764, 10.1152/jappl.1976.41.5.764

Rider, 2006, A safety review of long-acting β2-agonists in patients with asthma, J Am Osteopath Assoc, 106, 562

Riiser, 2006, The effect of formoterol inhalation on endurance performance in hypobaric conditions, Med Sci Sports Exerc, 38, 2132, 10.1249/01.mss.0000233801.46906.9b

10.1165/rcmb.2011-0061OC

10.1378/chest.112.1.19

10.1016/j.pupt.2008.10.008

10.1007/s00210-010-0533-6

Rossing, 2008, Carmoterol does not induce tolerance in COPD (Abstract), Proc Am Thorac Soc, 5, A962

10.1038/sj.bjp.0706096

10.1183/09031936.06.00027405

Ruffin, 1982, Assessment of β-adrenoceptor antagonists in asthmatic patients, Br J Clin Pharmacol, 13, 325S, 10.1111/j.1365-2125.1982.tb01937.x

10.1038/sj.bjp.0706669

10.1378/chest.10854

10.1016/j.tem.2004.05.004

Salama, 2011, Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease?, Expert Opin Pharmacother, 12, 1913, 10.1517/14656566.2011.589837

Salter, 1859, On some points in the treatment and clinical history of asthma, Edinburgh Med J, 4, 1109

Santus, 2007, Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting β2-agonists, Respir Med, 101, 1798, 10.1016/j.rmed.2007.02.007

Scarpace, 1988, Increased beta-adrenergic receptors in the light-density membrane fraction in lungs from senescent rats, J Gerontol, 43, B163, 10.1093/geronj/43.6.B163

10.2174/092986710789957841

10.1016/j.ejphar.2008.01.056

10.1016/j.jaci.2004.03.017

Scheinin, 1987, Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers, Br J Clin Pharmacol, 24, 645, 10.1111/j.1365-2125.1987.tb03224.x

Schering Corporation (2010) Foradil Aerolizer (formoterol fumarate). U.S. prescribing information. Available at http://www.spfiles.com/piforadil.pdf .

10.1038/sj.bjp.0703725

Schnapp, 2009, In vitro characterization of BI 1744 CL, a novel long acting β2 agonist: investigations to understand its long duration of action (Abstract), Am J Respir Crit Care Med, 179, A1919

Schultze-Werninghaus, 1982, The clinical and pharmacological history of theophylline: first report on the bronchospasmolytic action in man by S. R. Hirsch in Frankfurt (Main) 1922, Clin Allergy, 12, 211, 10.1111/j.1365-2222.1982.tb01641.x

10.1097/00045391-200309000-00006

Scullion, 2007, The development of anticholinergics in the management of COPD, Int J Chron Obstruct Pulmon Dis, 2, 33

10.1067/mai.2002.129966

Sears, 2011, The addition of long-acting beta-agonists to inhaled corticosteroids in asthma, Curr Opin Pulm Med, 17, 23, 10.1097/MCP.0b013e328341004c

10.1016/j.rmed.2004.07.003

10.1183/09031936.00145006

10.1016/0140-6736(90)93098-A

10.1038/sj.bjp.0702068

10.1001/archinte.159.9.989

10.1074/jbc.M506576200

10.1165/rcmb.2006-0358OC

Shibata, 2000, Teratogenic and fetal toxicity following intravenous theophylline administration in pregnant rabbits is related to maternal drug plasma levels, Methods Find Exp Clin Pharmacol, 22, 101, 10.1358/mf.2000.22.2.796072

10.1136/bmj.d2549

Sichletidis, 1999, Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD, Int J Clin Pract, 53, 185, 10.1111/j.1742-1241.1999.tb11699.x

Simons, 1987, Anticholinergic drugs and the airways: “time future contained in time past”, J Allergy Clin Immunol, 80, 239, 10.1016/0091-6749(87)90025-X

10.1016/j.annemergmed.2007.04.005

10.1136/thx.2007.087213

10.1186/1465-9921-11-26

Singh, 2011, Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD (Abstract), Eur Respir J, 38, 147s

10.1136/bmj.d3215

10.1001/jama.300.12.1439

Skoogh, 1986, Parasympathetic ganglia in the airways, Bull Eur Physiopathol Respir, 22, 143

Skorodin, 1986, Oxitropium bromide, a new anticholinergic bronchodilator, Ann Allergy, 56, 229

Smith, 1984, Metabolic responses to beta 2 stimulants, J R Coll Physicians Lond, 18, 190

10.1183/09031936.00139508

10.1152/physrev.00023.2003

Sousa, 2011, Sildenefil decreases rat tracheal hyperresponsiveness to carbochol and changes canonical transient receptor potential gene expression after antigen challenge, Braz J Med Biol Res, 44, 562, 10.1590/S0100-879X2011000600010

10.1183/09031936.00158208

Spina, 1995, Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus, Br J Pharmacol, 116, 2334, 10.1111/j.1476-5381.1995.tb15074.x

10.1016/S0024-3205(98)00432-9

10.1164/ajrccm/140.5.1410

Sporer, 2008, Inhaled salbutamol and doping control: effects of dose on urine concentrations, Clin J Sport Med, 18, 282, 10.1097/JSM.0b013e3181705c8c

10.1038/469172a

10.1007/BF00165134

10.1124/mol.110.069120

10.1001/archinternmed.2011.170

Sterling, 2011, Dose-related efficacy and optimal once-daily (OD) dosing interval of the long-acting beta2 agonist (LABA), vilanterol trifenatate (VI), in adults with persistent asthma (Abstract), Am J Respir Crit Care Med, 183, A4488

10.1016/j.rmed.2004.05.008

10.1124/jpet.107.129296

Sue-Chu, 1999, Salmeterol and physical performance at −15 degrees C in highly trained nonasthmatic cross-country skiers, Scand J Med Sci Sports, 9, 48, 10.1111/j.1600-0838.1999.tb00206.x

Sugiyama, 2010, Pharmacological profile of a novel bronchodilator, TEI3252, as bifunctional M3 antagonist and beta2 agonist (Abstract), Am J Respir Crit Care Med, 181, A4436

10.1016/S0140-6736(94)90127-9

10.1016/j.vascn.2008.06.003

Svedmyr, 1985, Fenoterol: a β2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects, Pharmacotherapy, 5, 109, 10.1002/j.1875-9114.1985.tb03409.x

Svedmyr, 1996, The use of β2-adrenoceptor agonists in the treatment of bronchial asthma, Pharmacol Toxicol, 78, 3, 10.1111/j.1600-0773.1996.tb00172.x

10.3109/03602538809049622

10.1164/ajrccm.156.1.9610113

Tasaka, 1986, Formoterol (Atock®): a new orally active and selective β2-receptor stimulant, Med Actual, 22, 505

10.1056/NEJMoa0805800

10.1080/15412550902724073

10.1016/0024-3205(93)90730-Q

10.1164/rccm.200901-0055CC

10.1136/thorax.55.9.762

10.1016/S1056-8719(99)00006-4

Timmer, 2010, Single doses of LAS100977, a novel long acting β2-agonist, show high activity and long duration in healthy subjects (Abstract), Am J Respir Crit Care Med, 181, A5663

Tjørhom, 2007, Effects of formoterol on endurance performance in athletes at an ambient temperature of −20 degrees C, Scand J Med Sci Sports, 17, 628, 10.1111/j.1600-0838.2006.00628.x

10.1164/rccm.200906-0937OC

10.1164/ajrccm.157.2.9708012

10.1007/BF00547042

10.1016/0006-2952(88)90068-8

10.1016/j.ejphar.2010.05.025

Tweel, 1971, TH1165a, a new bronchodilator: a clinical comparative evaluation with metaproterenol, Ann Allergy, 29, 142

10.1016/S0196-0644(85)80445-5

10.3346/jkms.2007.22.5.839

10.1111/j.1440-1843.2008.01259.x

United States Food and Drug Administration, Division of Pulmonary-Allergy Drugs Advisory Committee and Office of Surveillance and Epidemiology (2009) Clinical briefing document. NDA no. 21-395. Spiriva HandiHaler. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM190463.pdf .

10.1055/s-2004-815716

10.3109/15412555.2010.528812

10.1159/000026376

10.1016/j.pupt.2011.10.007

10.1183/09031936.05.00140404

10.1378/chest.129.3.509

10.1136/thx.2010.139113

10.1034/j.1399-3003.2000.15e11.x

10.1183/09031936.02.00238002

10.1016/j.pupt.2011.07.006

van Noord, 1998, A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction, Respir Med, 92, 1346, 10.1016/S0954-6111(98)90140-8

10.1183/09031936.96.09081684

10.1136/thx.46.5.355

10.1016/j.rmed.2010.04.006

10.1183/09031936.00068908

10.3109/15412555.2010.510158

10.1038/sj.bjp.0706724

10.1124/jpet.110.170035

10.1056/NEJMoa1008378

10.1016/j.rmed.2008.07.020

10.1186/1465-9921-11-135

Voss HP (1994) Long-acting β2-adrenoceptor agonists in asthma: molecular pharmacological aspects. Doctoral thesis, Vrije Universiteit, Amsterdam.

10.1016/0922-4106(92)90158-R

Wagner, 1978, Ventilation–perfusion inequality in asymptomatic asthma, Am Rev Respir Dis, 118, 511

Waldeck, 1976, An in vitro method for the study of β-receptor mediated effects on slow contracting skeletal muscle, J Pharm Pharmacol, 28, 434, 10.1111/j.2042-7158.1976.tb04649.x

10.1016/S0014-2999(02)01728-4

10.1111/j.1476-5381.2010.01178.x

Wang, 2011, Addition of theophylline or increasing the dose of inhaled corticosteroid in symptomatic asthma: a meta-analysis of randomized controlled trials, Yonsei Med J, 52, 268, 10.3349/ymj.2011.52.2.268

Ward, 1993, Theophylline—an immunomodulatory role in asthma?, Am Rev Respir Dis, 147, 518, 10.1164/ajrccm/147.3.518

10.1113/jphysiol.1995.sp020603

10.1183/09031936.00059409

10.1038/nature09746

Wasserman, 1974, Cardiovascular and bronchomotor responses to selective beta adrenergic receptor agonists in the anesthetized dog, J Pharmacol Exp Ther, 189, 445

10.1378/chest.80.3.292

10.1016/S0140-6736(09)61492-6

10.1164/rccm.200509-1519OC

10.1164/rccm.200904-0492OC

10.1136/thx.32.5.555

10.2165/00002018-200225030-00006

10.1016/j.ajog.2009.07.010

Woodcock, 2009, Single dose budesonide/carmoterol fixed combination improves lung function over 24 hours in patients with moderate to severe persistent asthma (Abstract), Eur Respir J, 34, 776s

10.1016/j.rmed.2010.11.027

10.1183/09031936.03.00067503

Wright, 2010, PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist in the anaesthetised dog model of bronchoconstriction (Abstract), Eur Respir J, 24, 1014s

10.1016/0140-6736(90)93099-B

10.1186/1465-9921-12-45

10.1007/s10928-010-9180-2

Yamamoto, 2002, Mutation screening of the muscarinic m2 and m3 receptor genes in asthmatics, outgrow subjects, and normal controls, Ann Genet, 45, 109, 10.1016/S0003-3995(02)01128-0

10.1042/bj2610001

10.1074/jbc.M110.212480

Yasui, 2000, Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism, J Leukoc Biol, 67, 529, 10.1002/jlb.67.4.529

Yohannes, 2011, Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes, Respir Care, 56, 477, 10.4187/respcare.00852

Young, 2011, AZD3199: a potent and selective beta2-adrenergic receptor agonist with rapid onset of action (Abstract), Am J Respir Crit Care Med, 183, A1585

Young, 2011, The in vivo profile of AZD3199: a novel, fast acting β2-agonist with a long duration of action (Abstract), Am J Respir Crit Care Med, 183, A1586

Yung, 1998, Randomised controlled trial of aminophylline for severe acute asthma, Arch Dis Child, 79, 405, 10.1136/adc.79.5.405

10.1016/0006-2952(95)00120-O

10.1378/chest.119.6.1661